Philipp K Roberts1, Peter L Nesper, Manjot K Gill, Amani A Fawzi. 1. *Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; and †Department of Ophthalmology, Medical University of Vienna, Vienna, Austria.
Abstract
PURPOSE: To perform a quantitative study of the vascular microstructure in actively treated choroidal neovascularization by optical coherence tomographic angiography. METHODS: Patients undergoing individualized anti-vascular endothelial growth factor therapy of minimum 12 months duration were included in this cross-sectional observational study and imaged using optical coherence tomographic angiography. En face optical coherence tomographic angiography images were analyzed for quantitative features, such as junction density, vessel length, and lacunarity using validated software (Angiotool). Patients were divided into 2 groups depending on their individualized treatment interval: "good responders, treated less frequently than 6 weeks" versus "poor responders, treated every 6 weeks or more frequently." Nonparametric testing was used to assess differences between these groups. RESULTS: Twenty-five eyes of 23 consecutive patients with a median 58-month history of choroidal neovascularization, treated by median of 34 anti-vascular endothelial growth factor injections, were included in the analysis. There was no significant difference between any of the microvascular choroidal neovascularization features between the 2 groups (P > 0.05). CONCLUSION: The semiautomated vessel segmentation software provides an objective and quantitative approach for choroidal neovascularization characterization. The consistently nonsignificant outcomes between the groups may provide evidence to support the "normalization hypothesis." This would suggest that regardless of treatment interval, individualized therapy in these eyes established vessel stability.
PURPOSE: To perform a quantitative study of the vascular microstructure in actively treated choroidal neovascularization by optical coherence tomographic angiography. METHODS:Patients undergoing individualized anti-vascular endothelial growth factor therapy of minimum 12 months duration were included in this cross-sectional observational study and imaged using optical coherence tomographic angiography. En face optical coherence tomographic angiography images were analyzed for quantitative features, such as junction density, vessel length, and lacunarity using validated software (Angiotool). Patients were divided into 2 groups depending on their individualized treatment interval: "good responders, treated less frequently than 6 weeks" versus "poor responders, treated every 6 weeks or more frequently." Nonparametric testing was used to assess differences between these groups. RESULTS: Twenty-five eyes of 23 consecutive patients with a median 58-month history of choroidal neovascularization, treated by median of 34 anti-vascular endothelial growth factor injections, were included in the analysis. There was no significant difference between any of the microvascular choroidal neovascularization features between the 2 groups (P > 0.05). CONCLUSION: The semiautomated vessel segmentation software provides an objective and quantitative approach for choroidal neovascularization characterization. The consistently nonsignificant outcomes between the groups may provide evidence to support the "normalization hypothesis." This would suggest that regardless of treatment interval, individualized therapy in these eyes established vessel stability.
Authors: Adriano Carnevali; Maria Vittoria Cicinelli; Vittorio Capuano; Federico Corvi; Andrea Mazzaferro; Lea Querques; Vincenzo Scorcia; Eric H Souied; Francesco Bandello; Giuseppe Querques Journal: Am J Ophthalmol Date: 2016-07-06 Impact factor: 5.258
Authors: Neil M Bressler; Quan V Doan; Rohit Varma; Paul P Lee; Ivan J Suñer; Chantal Dolan; Mark D Danese; Elaine Yu; Irwin Tran; Shoshana Colman Journal: Arch Ophthalmol Date: 2011-06
Authors: David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Juan E Grunwald; Ebenezer Daniel; Jiayan Huang; Gui-Shuang Ying; Maureen G Maguire; Cynthia A Toth; Glenn J Jaffe; Stuart L Fine; Barbara Blodi; Michael L Klein; Alison A Martin; Stephanie A Hagstrom; Daniel F Martin Journal: Ophthalmology Date: 2013-09-29 Impact factor: 12.079
Authors: Atsuro Uchida; Ming Hu; Amy Babiuch; Sunil K Srivastava; Rishi P Singh; Peter K Kaiser; Katherine Talcott; Aleksandra Rachitskaya; Justis P Ehlers Journal: PLoS One Date: 2019-06-25 Impact factor: 3.240
Authors: Philipp K Roberts; Markus Schranz; Alice Motschi; Sylvia Desissaire; Valentin Hacker; Michael Pircher; Stefan Sacu; Wolf Buehl; Christoph K Hitzenberger; Ursula M Schmidt-Erfurth Journal: Sci Rep Date: 2022-01-07 Impact factor: 4.379
Authors: Tristan T Hormel; Yali Jia; Yifan Jian; Thomas S Hwang; Steven T Bailey; Mark E Pennesi; David J Wilson; John C Morrison; David Huang Journal: Prog Retin Eye Res Date: 2020-07-24 Impact factor: 21.198
Authors: Florence Coscas; Diogo Cabral; Telmo Pereira; Carlos Geraldes; Hemaxi Narotamo; Alexandra Miere; Marco Lupidi; Alexandre Sellam; Ana Papoila; Gabriel Coscas; Eric Souied Journal: PLoS One Date: 2018-10-09 Impact factor: 3.240